- Home
- SEMR vs PCRX Comparison
SEMR vs PCRX Comparison
Compare SEMR & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SEMR
- PCRX
- Stock Information
- Founded
- SEMR 2008
- PCRX 2006
- Country
- SEMR United States
- PCRX United States
- Employees
- SEMR N/A
- PCRX N/A
- Industry
- SEMR EDP Services
- PCRX Biotechnology: Pharmaceutical Preparations
- Sector
- SEMR Technology
- PCRX Health Care
- Exchange
- SEMR Nasdaq
- PCRX Nasdaq
- Market Cap
- SEMR 1.1B
- PCRX 1.2B
- IPO Year
- SEMR 2021
- PCRX 2011
- Fundamental
- Price
- SEMR $7.41
- PCRX $27.12
- Analyst Decision
- SEMR Buy
- PCRX Buy
- Analyst Count
- SEMR 8
- PCRX 6
- Target Price
- SEMR $14.88
- PCRX $30.00
- AVG Volume (30 Days)
- SEMR 1.2M
- PCRX 634.1K
- Earning Date
- SEMR 11-06-2025
- PCRX 11-05-2025
- Dividend Yield
- SEMR N/A
- PCRX N/A
- EPS Growth
- SEMR N/A
- PCRX N/A
- EPS
- SEMR N/A
- PCRX N/A
- Revenue
- SEMR $413,962,000.00
- PCRX $705,848,000.00
- Revenue This Year
- SEMR $20.28
- PCRX $7.36
- Revenue Next Year
- SEMR $16.41
- PCRX $10.07
- P/E Ratio
- SEMR N/A
- PCRX N/A
- Revenue Growth
- SEMR 22.16
- PCRX 2.25
- 52 Week Low
- SEMR $7.01
- PCRX $12.61
- 52 Week High
- SEMR $18.74
- PCRX $27.64
- Technical
- Relative Strength Index (RSI)
- SEMR 40.42
- PCRX 64.42
- Support Level
- SEMR $7.32
- PCRX $25.63
- Resistance Level
- SEMR $7.90
- PCRX $27.11
- Average True Range (ATR)
- SEMR 0.23
- PCRX 0.90
- MACD
- SEMR 0.02
- PCRX -0.03
- Stochastic Oscillator
- SEMR 11.92
- PCRX 79.20
About SEMR SEMrush Holdings Inc.
SEMrush Holdings Inc is engaged in the online visibility management software-as-a-service (SaaS) platform. Its platform utilizes data and intelligence at the core surrounded by AI-powered interconnected hubs focused on search engine optimization, paid advertising, social media management, local marketing, brand marketing, and content marketing Geographically, it generates revenues from the United States, the UK, and Others.
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.